Top stories in hematology/oncology: Late effects of cancer treatment, HPV vaccination prevents cervical dysplasia recurrence
Click Here to Manage Email Alerts
Healio spoke with experts in oncology, internal medicine, cardiovascular medicine, rheumatology and endocrinology about the long-term effects of cancer treatment and how to help manage care for cancer survivors. It was the top story in hematology/oncology last week.
Another top story includes results from a systematic review that show women who received the HPV vaccine after surgical excision for high-grade cervical dysplasia had a lower risk for recurrence than women who did not.
Read these and more top stories in hematology/oncology below:
Chronic, late effects of cancer treatment: The consequences of a cure
Substantial improvements in cancer treatment during the past several decades are an unequivocal victory for oncology — making long-term survival a reality for many patients. As more cancer survivors look forward to full life spans, they face the increased possibility of chronic comorbidities and long-term treatment effects. Read more.
Adjuvant HPV vaccination lowers risk for high-grade cervical dysplasia recurrence
Women who received the HPV vaccine after surgical excision for high-grade cervical dysplasia had lower risk for recurrence than women who received placebo or surgery alone, according to results of a systemic review and meta-analysis presented at the virtual Society of Gynecologic Cancer Annual Meeting. Read more.
‘Sound evidence base’ needed amid growing acceptance of cannabis for patients with cancer
Medical cannabis is now legal in 33 states, most of which consider cancer a qualifying condition for its use in symptom palliation. Read more.
Long-term cancer survival increases need for cardiac care
Cancer survivors pose a unique challenge to primary care providers and cardiologists, as they are not only living longer but also presenting with competing risk factors. Read more.
FDA grants priority review to first-line lung cancer regimen
The FDA granted priority review to nivolumab plus ipilimumab combined with a limited chemotherapy course as first-line treatment for patients with metastatic or recurrent non-small cell lung cancer. Read more.